About Solute carrier family 35 member G1
Solute carrier family 35 member G1 (SLC35G1) is a protein
from Homo sapiens identified by UniProt accession
Q2M3R5, 365 residues long.
MolForge cross-references it against 0 known binders and
13 disease associations.
Target properties
| Protein name | Solute carrier family 35 member G1 |
|---|
| UniProt accession | Q2M3R5 |
|---|
| Gene | SLC35G1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 365 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (13)
Diseases linked to this target (Open Targets).
- visual perception measurement · score 0.33
- cannabis dependence measurement · score 0.32
- Familial prostate cancer · score 0.11
- prostate cancer · score 0.11
- prostate carcinoma · score 0.11
- waist-hip ratio · score 0.06
- esophageal squamous cell carcinoma · score 0.02
- ulcerative colitis · score 0.01
- Crohn's disease · score 0.00
- infect · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q2M3R5-F1 | alphafold | PREDICTED | 80.15 | — |
Amino-acid sequence (365 residues)
MRPQDSTGVA ELQEPGLPLT DDAPPGATEE PAAAEAAGAP DRGRCWLCLS SPCCSRTEPE AKKKAPCPGL GLFYTLLSAF LFSVGSLFVK KVQDVHAVEI SAFRCVFQML VVIPCLIYRK TGFIGPKGQR IFLILRGVLG STAMMLIYYA YQTMSLADAT VITFSSPVFT SIFAWICLKE KYSPWDALFT VFTITGVILI VRPPFLFGSD TSGMEESYSG HLKGTFAAIG SAVFAASTLV ILRKMGKSVD YFLSIWYYVV LGLVESVIIL SVLGEWSLPY CGLDRLFLIF IGLFGLGGQI FITKALQIEK AGPVAIMKTM DVVFAFIFQI IFFNNVPTWW TVGGALCVVA SNVGAAIRKW YQSSK
Explore Solute carrier family 35 member G1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets